ES2130257T3 - Nuevos compuestos y conjugados. - Google Patents

Nuevos compuestos y conjugados.

Info

Publication number
ES2130257T3
ES2130257T3 ES93909297T ES93909297T ES2130257T3 ES 2130257 T3 ES2130257 T3 ES 2130257T3 ES 93909297 T ES93909297 T ES 93909297T ES 93909297 T ES93909297 T ES 93909297T ES 2130257 T3 ES2130257 T3 ES 2130257T3
Authority
ES
Spain
Prior art keywords
compound
group
enzyme
conjugates
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909297T
Other languages
English (en)
Inventor
Paul S Palumbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Behring Diagnostics Inc
Original Assignee
Behring Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behring Diagnostics Inc filed Critical Behring Diagnostics Inc
Application granted granted Critical
Publication of ES2130257T3 publication Critical patent/ES2130257T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

UN COMPUESTO REPRESENTADO POR FORMULA (I), EN DONDE X ES UN GRUPO SEPARADOR. EL COMPUESTO SE USA PARA CONJUGAR UN COMPUESTO QUE TIENE UN GRUPO ALCOHOL SOBRE UN GRUPO AMINA A UN COMPUESTO QUE TIENE UN GRUPO TIOL. EL COMPUESTO PUEDE SER USADO PARA CONJUGAR UN GRUPO BIOLOGICAMENTE ACTIVO TAL COMO UN ANTIGENO O UNA PROTEINA TAL COMO UNA ENZIMA PARA PROPORCIONAR UNA ENZIMA ANTIGENO ETIQUETADA PARA USO EN METODOS DE INMUNOENSAYO DE AMPLIFICACION DE ENZIMA PARA ANALITOS O METABOLITOS EN MUESTRAS FLUIDAS. EL COMPUESTO TAMBIEN SE PUEDE USAR PARA INMOBILIZAR UN MATERIAL TAL COMO UNA PROTEINA A UN SOPORTE SOLIDO.
ES93909297T 1992-04-23 1993-04-08 Nuevos compuestos y conjugados. Expired - Lifetime ES2130257T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/872,539 US5294536A (en) 1992-04-23 1992-04-23 Conjugates

Publications (1)

Publication Number Publication Date
ES2130257T3 true ES2130257T3 (es) 1999-07-01

Family

ID=25359788

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909297T Expired - Lifetime ES2130257T3 (es) 1992-04-23 1993-04-08 Nuevos compuestos y conjugados.

Country Status (9)

Country Link
US (1) US5294536A (es)
EP (1) EP0606411B1 (es)
JP (1) JPH06508639A (es)
AT (1) ATE177113T1 (es)
AU (1) AU662627B2 (es)
CA (1) CA2101734A1 (es)
DE (1) DE69323713T2 (es)
ES (1) ES2130257T3 (es)
WO (1) WO1993022677A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0629292A1 (en) * 1993-01-06 1994-12-21 Beckman Instruments, Inc. Method for making a preconjugate
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
DE69528523T2 (de) * 1994-04-08 2003-06-12 Receptagen Corp., Edmonds Rezeptor modulierendes mitteln und entsprechendes verfahren
US5739287A (en) * 1994-04-08 1998-04-14 University Of Washington Biotinylated cobalamins
SE9600229D0 (sv) * 1996-01-23 1996-01-23 Pharmacia Ab Novel potentiating agents
DE69738454D1 (de) 1996-05-20 2008-02-21 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5977299A (en) 1997-04-07 1999-11-02 Dade Behring Marburg Gmbh Activated peptides and conjugates
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
US6210908B1 (en) 1998-11-11 2001-04-03 Dade Behring Marburg Gmbh Activated peptides and conjugates
US6743585B2 (en) 1999-09-16 2004-06-01 Agilent Technologies, Inc. Methods for preparing conjugates
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
CN107973836B (zh) * 2017-10-19 2020-05-12 苏州博源医疗科技有限公司 醛固酮衍生物及其制备方法、醛固酮均相酶免疫检测试剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4760142A (en) * 1984-11-27 1988-07-26 Hoechst Celanese Corporation Divalent hapten derivatives
JPH01199573A (ja) * 1987-10-25 1989-08-10 Kuraray Co Ltd スーパーオキシドジスムターゼ誘導体およびその製造法
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
AU626809B2 (en) * 1987-10-30 1992-08-13 Abbott Laboratories Heterobifunctional coupling agents
CA2015938C (en) * 1989-05-02 1999-09-07 Kevin M. Knigge Covalent attachment of specific binding members to a solid phase

Also Published As

Publication number Publication date
CA2101734A1 (en) 1993-10-24
DE69323713T2 (de) 1999-07-01
DE69323713D1 (de) 1999-04-08
ATE177113T1 (de) 1999-03-15
AU662627B2 (en) 1995-09-07
US5294536A (en) 1994-03-15
AU3976393A (en) 1993-11-29
JPH06508639A (ja) 1994-09-29
WO1993022677A1 (en) 1993-11-11
EP0606411B1 (en) 1999-03-03
EP0606411A1 (en) 1994-07-20

Similar Documents

Publication Publication Date Title
ES2130257T3 (es) Nuevos compuestos y conjugados.
ATE130197T1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
KR870003195A (ko) 단일클론 항체를 이용한 그램 네가티브 박테리아 감염증의 검진 방법
DK0693132T3 (da) Rapamycinassay
DE68922385D1 (de) Neuer monoklonaler Antikörper gegen menschliches Karzinom.
FI891012A (fi) Menetelmä ja väline immuunikokeissa esiintyvien häiriötekijöiden kompensoimiseksi
DE3855816D1 (de) Chromatographisches Material
ES2123677T3 (es) Ligadores de maleinimida trifuncionales homobidentados y su uso en conjugados inmunologicamente activos.
ES8506902A1 (es) Un procedimiento para la purificacion de un antigeno.
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
ES2148144T3 (es) Procedimiento para la estabilizacion de conjugados de enzima.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
EP0028132A3 (en) Method of passively adsorbing immuno-reactive haptens to solid phases
FR2373795A1 (fr) Dosage immunologique par enzyme fixee
NO874937D0 (no) Stabil immobilisert haptenreagens for anvendelse i hetrogene, immunometriske analyser.
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
CA2117536A1 (en) Immunological detection of organophosphates
KR880010775A (ko) 면역글로로불린 결합체
FR2422699A1 (fr) Procede de preparation d'un materiau solide poreux revetu de cellulose ou de cellulose modifiee
DE69025023D1 (de) Peptide und deren Benutzung
ES2141105T3 (es) Peptidos ramificados en ensayos para anticuerpos.
EA200100287A1 (ru) Высокоаффинные антитела
DE3851221D1 (de) Nichttrennender festphasen-enzymtest.
ES2092606T3 (es) Anticuerpos monoclonales para polimeros sulfonados.
FI86255B (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 606411

Country of ref document: ES